We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
Read MoreHide Full Article
Seagen Inc. is making good progress with its portfolio of marketed drugs — Adcetris, Padcev, Tukysa and the newly approved Tivdak — targeting different types of cancer indications.
All these drugs have witnessed strong uptake so far, with Adcetris being the majority contributor to Seagen’s top line. The drug has been approved by the FDA for six cancer indications.
Several label expansion studies on Adcetris, Padcev, Tukysa and Tivdak are currently underway, wherein a potential approval is likely to drive sales further in 2022 and beyond.
The company’s top line mainly comprises product revenues, collaboration and license agreement revenues, and royalties.
Shares of Segen have rallied 13.6% this year against the industry’s decrease of 18.5%.
Image Source: Zacks Investment Research
Recently, shares of SGEN surged significantly, following rumors of a potential acquisition by pharma giant Merck & Co., Inc. (MRK - Free Report) .
Merck has been engaged in advanced talks with Seagen for potentially buying out the latter, per a Wall Street Journal article.
Both Seagen and Merck are yet to confirm the validity of the news through a formal statement. There is no guarantee that Merck would make a potential buyout offer.
Meanwhile, in May 2022, Seagen appointed Roger Dansey as the interim chief executive officer, after the company’s current CEO, president and member of its board of directors, Dr. Clay Siegall, resigned from all of his positions.
Although Seagen is riding high on the success of its portfolio of marketed drugs, it remains to be seen whether the company can continue its impressive growth trajectory and drive revenues further in future years. The approval for Tivdak has added a fourth drug to Seagen’s portfolio, which is likely to drive sales in the days ahead. Stiff competition in the market also remains a concern.
Bio-Techne’s earnings estimates have been revised 0.2% upward for 2022 and 0.7% upward for 2023 in the past 60 days.
Earnings of Bio-Techne have surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. TECH delivered an earnings surprise of 3.30%, on average.
Atara Biotherapeutics’ loss per share estimates narrowed 9.2% for 2022 and 18.2% for 2023 in the past 60 days.
Earnings of Atara Biotherapeutics have surpassed estimates in three of the trailing four quarters and missed on the other occasion. ATRA delivered an earnings surprise of 4.83%, on average.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
Seagen Inc. is making good progress with its portfolio of marketed drugs — Adcetris, Padcev, Tukysa and the newly approved Tivdak — targeting different types of cancer indications.
All these drugs have witnessed strong uptake so far, with Adcetris being the majority contributor to Seagen’s top line. The drug has been approved by the FDA for six cancer indications.
Several label expansion studies on Adcetris, Padcev, Tukysa and Tivdak are currently underway, wherein a potential approval is likely to drive sales further in 2022 and beyond.
The company’s top line mainly comprises product revenues, collaboration and license agreement revenues, and royalties.
Shares of Segen have rallied 13.6% this year against the industry’s decrease of 18.5%.
Image Source: Zacks Investment Research
Recently, shares of SGEN surged significantly, following rumors of a potential acquisition by pharma giant Merck & Co., Inc. (MRK - Free Report) .
Merck has been engaged in advanced talks with Seagen for potentially buying out the latter, per a Wall Street Journal article.
Both Seagen and Merck are yet to confirm the validity of the news through a formal statement. There is no guarantee that Merck would make a potential buyout offer.
Meanwhile, in May 2022, Seagen appointed Roger Dansey as the interim chief executive officer, after the company’s current CEO, president and member of its board of directors, Dr. Clay Siegall, resigned from all of his positions.
Although Seagen is riding high on the success of its portfolio of marketed drugs, it remains to be seen whether the company can continue its impressive growth trajectory and drive revenues further in future years. The approval for Tivdak has added a fourth drug to Seagen’s portfolio, which is likely to drive sales in the days ahead. Stiff competition in the market also remains a concern.
Seagen Inc. Price and Consensus
Seagen Inc. price-consensus-chart | Seagen Inc. Quote
Zacks Rank & Stocks to Consider
Seagen currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector include Bio-Techne Corporation (TECH - Free Report) and Atara Biotherapeutics, Inc. (ATRA - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Bio-Techne’s earnings estimates have been revised 0.2% upward for 2022 and 0.7% upward for 2023 in the past 60 days.
Earnings of Bio-Techne have surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. TECH delivered an earnings surprise of 3.30%, on average.
Atara Biotherapeutics’ loss per share estimates narrowed 9.2% for 2022 and 18.2% for 2023 in the past 60 days.
Earnings of Atara Biotherapeutics have surpassed estimates in three of the trailing four quarters and missed on the other occasion. ATRA delivered an earnings surprise of 4.83%, on average.